安罗替尼治疗晚期非小细胞肺癌患者的疗效及对患者生活质量的影响<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2025.06.003

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1284 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the efficacy of Anlotinib in the treatment of patients with advanced non-small cell lung cancer (NSCLC) and its influence on quality of life. 【Methods】A total of 98 patients with advanced NSCLC treated in our hospital from August 2022 to August 2024 were selected and divided into control group (given conventional chemotherapy) and observation group (given Anlotinib on the basis of conventional chemotherapy) according to different treatment methods, with 49 cases in each group. The clinical efficacy, serum indexes, quality of life and incidence of adverse reactions were compared between the two groups. 【Results】The disease control rate and overall response rate of the observation group were higher than those of the control group (P<0.05). After treatment, the levels of vascular endothelial growth factor (VEGF), carbohydrate antigen 125 (CA125) and matrix metalloproteinase-9 (MMP-9) in the observation group were lower than those in the control group (P<0.05). After treatment, the score of Generic Quality of Life Inventory (GQOLI-74) in the observation group was higher than that in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the observation group and the control group (P>0.05). 【Conclusion】Anlotinib combined with conventional chemotherapy has significant efficacy in the treatment of patients with advanced NSCLC, which can significantly improve the quality of life of patients, significantly down-regulate the levels of biomarkers related to tumor angiogenesis, invasion and metastasis, and has good safety.

Key words： Carcinoma, Non-Small-Cell Lung Antineoplastic Agents Quality of Life Treatment Outcome

Received: 31 March 2025

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Xiao
	CHEN Gaoying
	SHANG Yan

Cite this article:

WANG Xiao,CHEN Gaoying,SHANG Yan. Efficacy of Anlotinib in the Treatment of Advanced Non-Small Cell Lung Cancer and its Influence on Quality of Life[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(6): 920-922.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.06.003 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I6/920

[1] 郝卓鸿,云铎,张颖,等. 非小细胞肺癌围手术期免疫治疗研究进展[J].首都医科大学学报,2024,45(4):666-677.
[2] 王天鸣,张良,程颖. 非小细胞肺癌免疫相关性肺炎研究进展[J].肿瘤防治研究,2023,50(8):808-812.
[3] 张萌,王永伏,杜晓娜. 贞芪扶正胶囊联合安罗替尼治疗非小细胞肺癌的效果及对患者免疫功能的影响[J].检验医学与临床,2025,22(2):223-226.
[4] 张莳,唐家宏. 程序性死亡受体1抑制剂与安罗替尼联合治疗晚期非小细胞肺癌的临床效果[J].解放军药学学报,2024,37(5):472-476.
[5] 洪乔军,韩冬冬,方瑜,等. 免疫检查点抑制剂联合安罗替尼治疗晚期非小细胞肺癌的临床疗效[J].临床药物治疗杂志,2024,22(8):63-68.
[6] 张春晓,张群妹,鲁广建. 安罗替尼联合多西他赛用于酪氨酸激酶抑制剂联合含铂类化疗失败非小细胞肺癌患者的疗效[J].中国药物应用与监测,2024,21(2):110-113.
[7] 陆雁,王芹,苏羚子,等. 中医益气养阴解毒方案联合安罗替尼治疗晚期非小细胞肺癌的疗效与安全性分析[J].上海中医药杂志,2022,56(8):54-58.
[8] 王爱芳,刘玉慧,李方旭. 胸腔镜肺叶切除术对老年早期肺癌患者的临床效果及对氧化应激相关分子的影响[J].实用癌症杂志,2023,38(1):160-163.
[9] 盛舒,卯云烨,翟今朝,等. EGFR 20外显子插入突变非小细胞肺癌的诊疗现状及进展[J].现代肿瘤医学,2024,32(17):3392-3397.
[10] 张良,杨长良,李佩东,等. HER-2突变晚期非小细胞肺癌的研究进展[J].肿瘤防治研究,2025,52(2):87-92.
[11] 武阳,陆翰杰,水会锋. 既往免疫经治的晚期非小细胞肺癌患者接受安罗替尼联合PD-1单抗的疗效及安全性[J].实用医学杂志,2023,39(5):572-578.
[12] 张群,刘振昌,赵亮,等. 安罗替尼胶囊联合培美曲赛注射液和顺铂注射液治疗非鳞状非小细胞肺癌患者的临床研究[J].中国临床药理学杂志,2023,39(7):932-935.
[13] 杨光霞,程云涛,刘琳琳,等. 安罗替尼联合厄洛替尼治疗表皮生长因子受体突变阳性晚期非小细胞肺癌患者的临床研究[J].中国临床药理学杂志,2023,39(20):2905-2909.
[14] 张晓娟,岳冬丽,杨双宁,等. 卡瑞利珠单抗联合安罗替尼三线治疗晚期非小细胞肺癌的疗效观察[J].肿瘤防治研究,2023,50(6):593-597.
[15] 王惠,凌青霞. 阿帕替尼联合TACE治疗中晚期肝癌患者的疗效及对其血清AFP、CA125、CA199水平的影响[J].医学临床研究,2023,40(2):183-186.